Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs.

Zackon AYL, Ayers AA, Yeager KA, Somma ML, Friedberg JW, Flowers CR, Nastoupil LJ.

Leuk Lymphoma. 2019 Jun 4:1-9. doi: 10.1080/10428194.2019.1594217. [Epub ahead of print]

PMID:
31164024
2.

Pathogen molecular pattern receptor agonists: treating cancer by mimicking infection.

Aleynick M, Svensson-Arvelund J, Flowers CR, Marabelle A, Brody JD.

Clin Cancer Res. 2019 May 23. pii: clincanres.1800.2019. doi: 10.1158/1078-0432.CCR-18-1800. [Epub ahead of print]

PMID:
31123052
3.

Racial and Socioeconomic Disparities in Mantle Cell Lymphoma.

Shah NN, Xi Y, Liu Y, Koff JL, Flowers CR, Behera M, Cohen JB.

Clin Lymphoma Myeloma Leuk. 2019 Mar 12. pii: S2152-2650(18)31720-8. doi: 10.1016/j.clml.2019.03.006. [Epub ahead of print]

PMID:
31029647
4.

Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma.

Gopalsamy SN, Rosenthal KM, Ayers AA, Goy A, Leonard JP, Vose JM, Obholz KL, Armitage JO, Flowers CR.

Leuk Lymphoma. 2019 Mar 8:1-9. doi: 10.1080/10428194.2019.1574006. [Epub ahead of print]

PMID:
30848966
5.

Reply to M.A. Slavin et al.

Taplitz RA, Kennedy EB, Flowers CR.

J Clin Oncol. 2019 May 1;37(13):1140-1141. doi: 10.1200/JCO.18.02227. Epub 2019 Mar 7. No abstract available.

PMID:
30844317
6.

Residential ambient benzene exposure in the United States and subsequent risk of hematologic malignancies.

Teras LR, Diver WR, Deubler EL, Krewski D, Flowers CR, Switchenko JM, Gapstur SM.

Int J Cancer. 2019 Feb 9. doi: 10.1002/ijc.32202. [Epub ahead of print]

PMID:
30737780
7.

PET-derived tumor metrics predict DLBCL response and progression-free survival.

Islam P, Goldstein J, Flowers CR.

Leuk Lymphoma. 2019 Feb 4:1-7. doi: 10.1080/10428194.2018.1562181. [Epub ahead of print]

PMID:
30714446
8.

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.

Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH.

Lancet Haematol. 2019 Feb;6(2):e100-e109. doi: 10.1016/S2352-3026(18)30216-3.

PMID:
30709431
9.

A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.

Çağlayan Ç, Goldstein JS, Ayer T, Rai A, Flowers CR.

Cancer. 2019 Jun 1;125(11):1837-1847. doi: 10.1002/cncr.31981. Epub 2019 Feb 1.

10.

Influenza Vaccination Documentation Rates During the First Year After Diagnosis of Diffuse Large B Cell Lymphoma.

Chang A, Payne JB, Allen PB, Koff JL, Ahmed R, Flowers CR, Bednarczyk RA.

Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):239-243. doi: 10.1016/j.clml.2018.12.018. Epub 2019 Jan 2.

PMID:
30686773
11.

Microsimulation Modeling in Oncology.

Çağlayan Ç, Terawaki H, Chen Q, Rai A, Ayer T, Flowers CR.

JCO Clin Cancer Inform. 2018 Dec;2:1-11. doi: 10.1200/CCI.17.00029.

12.

Identifying and Addressing Disparities in Survival Outcomes for Rural Patients With Cancer.

McCullough LE, Flowers CR.

JAMA Netw Open. 2018 Aug 3;1(4):e181243. doi: 10.1001/jamanetworkopen.2018.1243. No abstract available.

PMID:
30646109
13.

Informatics Approaches to Address New Challenges in the Classification of Lymphoid Malignancies.

Jordan J, Goldstein JS, Jaye DL, Gurcan M, Flowers CR, Cooper LAD.

JCO Clin Cancer Inform. 2018;2. doi: 10.1200/CCI.17.00039. Epub 2018 Feb 9.

14.

Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study.

Ritter AJ, Goldstein JS, Ayers AA, Flowers CR.

Leuk Lymphoma. 2019 Jan 11:1-12. doi: 10.1080/10428194.2018.1546855. [Epub ahead of print]

PMID:
30632824
15.

Clinical Implications of Febrile Neutropenia Guidelines in the Cancer Patient Population.

Braga CC, Taplitz RA, Flowers CR.

J Oncol Pract. 2019 Jan;15(1):25-26. doi: 10.1200/JOP.18.00718. No abstract available.

PMID:
30629901
16.

Reply to H.J.A. Adams et al.

Shi Q, Flowers CR.

J Clin Oncol. 2019 Feb 20;37(6):526-527. doi: 10.1200/JCO.18.02022. Epub 2018 Dec 28. No abstract available.

PMID:
30592641
17.

Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.

Funk CR, Petersen CT, Jagirdar N, Ravindranathan S, Jaye DL, Flowers CR, Langston A, Waller EK.

Int J Mol Sci. 2018 Dec 19;19(12). pii: E4118. doi: 10.3390/ijms19124118.

18.

Intrathecal Central Nervous System Prophylaxis in Patients With Diffuse Large B-cell Lymphoma at an Academic Healthcare System.

Hall KH, Valla K, Flowers CR, Cohen JB.

Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):89-94. doi: 10.1016/j.clml.2018.11.014. Epub 2018 Nov 17.

PMID:
30528416
19.

Novel immunotherapy approaches to follicular lymphoma.

Flowers CR, Leonard JP, Nastoupil LJ.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):194-199. doi: 10.1182/asheducation-2018.1.194. Review.

PMID:
30504310
20.

Sequencing of therapies in relapsed follicular lymphoma.

Nastoupil LJ, Flowers CR, Leonard JP.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):189-193. doi: 10.1182/asheducation-2018.1.189. Review.

PMID:
30504309
21.

Where to start? Upfront therapy for follicular lymphoma in 2018.

Leonard JP, Nastoupil LJ, Flowers CR.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):185-188. doi: 10.1182/asheducation-2018.1.185. Review.

PMID:
30504308
22.

Safety and survival outcomes for bloodless transplantation in patients with myeloma.

Joseph NS, Kaufman JL, Boise LH, Valla K, Almaula DK, Obidike CO, Langston AA, Waller EK, Khoury HJ, Flowers CR, Graiser M, Heffner LT, Lonial S, Nooka AK.

Cancer. 2019 Jan 15;125(2):185-193. doi: 10.1002/cncr.31677. Epub 2018 Nov 27. Review.

PMID:
30480777
23.

What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?

Flowers CR, Ramsey SD.

J Clin Oncol. 2018 Oct 2:JCO2018793570. doi: 10.1200/JCO.2018.79.3570. [Epub ahead of print] No abstract available.

PMID:
30277825
24.

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.

Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ.

Leuk Lymphoma. 2019 Apr;60(4):940-946. doi: 10.1080/10428194.2018.1515944. Epub 2018 Oct 2.

PMID:
30277110
25.

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.

Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD.

Leuk Lymphoma. 2019 Apr;60(4):894-903. doi: 10.1080/10428194.2018.1515940. Epub 2018 Oct 2.

PMID:
30277102
26.

The association of physical activity before and after lymphoma diagnosis with survival outcomes.

Pophali PA, Ip A, Larson MC, Rosenthal AC, Maurer MJ, Flowers CR, Link BK, Farooq U, Feldman AL, Allmer C, Slager SL, Witzig TE, Habermann TM, Cohen JB, Cerhan JR, Thompson CA.

Am J Hematol. 2018 Dec;93(12):1543-1550. doi: 10.1002/ajh.25288. Epub 2018 Oct 17.

PMID:
30230581
27.

Reply to J.A. Talcott.

Taplitz RA, Kennedy EB, Flowers CR.

J Clin Oncol. 2018 Sep 4:JCO2018793141. doi: 10.1200/JCO.2018.79.3141. [Epub ahead of print] No abstract available.

PMID:
30179568
28.

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.

Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, Strasfeld L, Flowers CR.

J Clin Oncol. 2018 Oct 20;36(30):3043-3054. doi: 10.1200/JCO.18.00374. Epub 2018 Sep 4.

PMID:
30179565
29.

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Summary.

Taplitz RA, Kennedy EB, Flowers CR.

J Oncol Pract. 2018 Sep 4:JOP1800366. doi: 10.1200/JOP.18.00366. [Epub ahead of print] No abstract available.

PMID:
30179525
30.

Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States.

Blum KA, Keller FG, Castellino S, Phan A, Flowers CR.

Br J Haematol. 2018 Nov;183(3):385-399. doi: 10.1111/bjh.15532. Epub 2018 Aug 10.

PMID:
30095154
31.

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.

de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, Ross JA, Salem AH, Verdugo M, Agarwal S, Zhou L, Kozloff M, Nastoupil LJ, Flowers CR.

Ann Oncol. 2018 Sep 1;29(9):1932-1938. doi: 10.1093/annonc/mdy256.

32.

Disparities in survival by insurance status in follicular lymphoma.

Goldstein JS, Nastoupil LJ, Han X, Jemal A, Ward E, Flowers CR.

Blood. 2018 Sep 13;132(11):1159-1166. doi: 10.1182/blood-2018-03-839035. Epub 2018 Jul 24.

PMID:
30042094
33.

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Habermann TM, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Coiffier B, Flowers CR.

J Clin Oncol. 2018 Sep 1;36(25):2593-2602. doi: 10.1200/JCO.2018.77.9124. Epub 2018 Jul 5.

34.

How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis.

Hall KH, Panjic EH, Valla K, Flowers CR, Cohen JB.

Oncology (Williston Park). 2018 Jun;32(6):303-9. Review.

35.

Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma.

Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB.

Leuk Lymphoma. 2018 Dec;59(12):2862-2870. doi: 10.1080/10428194.2018.1455973. Epub 2018 Jun 18.

PMID:
29912594
36.

The need to assess financial adverse events.

Nastoupil LJ, Prasad V, Flowers CR.

Lancet Haematol. 2018 Nov;5(11):e508-e509. doi: 10.1016/S2352-3026(18)30072-3. Epub 2018 Jun 12. No abstract available.

PMID:
29907551
37.

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B.

Ann Oncol. 2018 Aug 1;29(8):1822-1827. doi: 10.1093/annonc/mdy203.

PMID:
29897404
38.

Targeting the B cell receptor pathway in non-Hodgkin lymphoma.

Valla K, Flowers CR, Koff JL.

Expert Opin Investig Drugs. 2018 Jun;27(6):513-522. doi: 10.1080/13543784.2018.1482273. Epub 2018 Jun 7. Review.

39.

Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.

Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, Etzioni R, McKenna MT, Oeffinger KC, Shih YT, Walter LC, Andrews KS, Brawley OW, Brooks D, Fedewa SA, Manassaram-Baptiste D, Siegel RL, Wender RC, Smith RA.

CA Cancer J Clin. 2018 Jul;68(4):250-281. doi: 10.3322/caac.21457. Epub 2018 May 30.

40.

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.

Wang SS, Carrington M, Berndt SI, Slager SL, Bracci PM, Voutsinas J, Cerhan JR, Smedby KE, Hjalgrim H, Vijai J, Morton LM, Vermeulen R, Paltiel O, Vajdic CM, Linet MS, Nieters A, de Sanjose S, Cozen W, Brown EE, Turner J, Spinelli JJ, Zheng T, Birmann BM, Flowers CR, Becker N, Holly EA, Kane E, Weisenburger D, Maynadie M, Cocco P, Albanes D, Weinstein SJ, Teras LR, Diver WR, Lax SJ, Travis RC, Kaaks R, Riboli E, Benavente Y, Brennan P, McKay J, Delfau-Larue MH, Link BK, Magnani C, Ennas MG, Latte G, Feldman AL, Doo NW, Giles GG, Southey MC, Milne RL, Offit K, Musinsky J, Arslan AA, Purdue MP, Adami HO, Melbye M, Glimelius B, Conde L, Camp NJ, Glenn M, Curtin K, Clavel J, Monnereau A, Cox DG, Ghesquières H, Salles G, Bofetta P, Foretova L, Staines A, Davis S, Severson RK, Lan Q, Brooks-Wilson A, Smith MT, Roman E, Kricker A, Zhang Y, Kraft P, Chanock SJ, Rothman N, Hartge P, Skibola CF.

Cancer Res. 2018 Jul 15;78(14):4086-4096. doi: 10.1158/0008-5472.CAN-17-2900. Epub 2018 May 7.

41.

Ethnic disparity in primary cutaneous CD30+ T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer database.

Feldman AL, Flowers CR.

Br J Haematol. 2018 Jun;181(6):721-722. doi: 10.1111/bjh.15221. Epub 2018 Apr 20. No abstract available.

PMID:
29676455
42.

Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors.

Keegan THM, Li Q, Steele A, Alvarez EM, Brunson A, Flowers CR, Glaser SL, Wun T.

Cancer Causes Control. 2018 Jun;29(6):551-561. doi: 10.1007/s10552-018-1025-0. Epub 2018 Apr 13.

43.

Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study.

Link BK, Day BM, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR, Flowers CR, Friedberg JW.

Br J Haematol. 2019 Feb;184(4):660-663. doi: 10.1111/bjh.15149. Epub 2018 Apr 2. No abstract available.

PMID:
29611177
44.

Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation.

Becnel M, Flowers CR, Nastoupil LJ.

Ann Lymphoma. 2017 Nov;1. pii: 8. doi: 10.21037/aol.2017.11.01. Epub 2017 Nov 17.

45.

Impact of the posttransplant lymphoproliferative disorder subtype on survival.

Koff JL, Li JX, Zhang X, Switchenko JM, Flowers CR, Waller EK.

Cancer. 2018 Jun 1;124(11):2327-2336. doi: 10.1002/cncr.31339. Epub 2018 Mar 26.

46.

Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.

Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB.

Cancer. 2018 Jun 1;124(11):2306-2315. doi: 10.1002/cncr.31328. Epub 2018 Mar 26.

47.

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update Summary.

Taplitz RA, Kennedy EB, Flowers CR.

J Oncol Pract. 2018 Apr;14(4):250-255. doi: 10.1200/JOP.18.00016. Epub 2018 Mar 8. No abstract available.

PMID:
29517953
48.

Balancing patient value and payer cost in hematologic malignancies: can it be done?

Allen PB, Flowers CR.

Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):123-126. doi: 10.1080/14737167.2018.1444478. Epub 2018 Mar 13. No abstract available.

49.

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.

Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR.

J Clin Oncol. 2018 May 10;36(14):1443-1453. doi: 10.1200/JCO.2017.77.6211. Epub 2018 Feb 20.

PMID:
29461916
50.

Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect® CLL cohort study.

Flowers CR, Nabhan C, Kay NE, Mato A, Lamanna N, Farber CM, Davids MS, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP.

Leuk Lymphoma. 2018 Oct;59(10):2327-2335. doi: 10.1080/10428194.2018.1427860. Epub 2018 Feb 7.

PMID:
29415595

Supplemental Content

Loading ...
Support Center